Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Oraltek** is an INMUNOTEK-branded, prescription allergen-specific sublingual immunotherapy product line composed of glycerinated native allergen extracts administered as an under-the-tongue spray. Individual Oraltek preparations can contain clinically selected aeroallergen extracts, including house dust mites, pollens, animal epithelia, and fungi. Repeated sublingual exposure is intended to induce allergen-specific immune tolerance and reduce IgE-mediated respiratory allergic disease symptoms and rescue-medication requirements. The product is supplied as a pineapple-flavoured spray, commonly at 30,000 therapeutic units per mL, with maintenance dosing initiated on the first treatment day. INMUNOTEK manufactures Oraltek, and the product has been commercialized in China with HOB Biotech. ([inmunotek.com](https://www.inmunotek.com/en/extracts-and-vaccines/allergen-vaccines/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oraltek.